NASDAQ:VSTM Verastem (VSTM) Stock Price, News & Analysis $2.40 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.34▼$2.4550-Day Range$2.20▼$3.6852-Week Range$2.10▼$14.22Volume413,484 shsAverage Volume499,814 shsMarket Capitalization$60.78 millionP/E RatioN/ADividend YieldN/APrice Target$14.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Verastem alerts: Email Address Verastem MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside518.1% Upside$14.83 Price TargetShort InterestBearish5.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.08Based on 4 Articles This WeekInsider TradingSelling Shares$107 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.54) to ($2.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.24 out of 5 starsMedical Sector475th out of 910 stocksPharmaceutical Preparations Industry222nd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingVerastem has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVerastem has only been the subject of 4 research reports in the past 90 days.Read more about Verastem's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.38% of the float of Verastem has been sold short.Short Interest Ratio / Days to CoverVerastem has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Verastem has recently increased by 7.07%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVerastem does not currently pay a dividend.Dividend GrowthVerastem does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VSTM. Previous Next 2.3 News and Social Media Coverage News SentimentVerastem has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Verastem this week, compared to 3 articles on an average week.Search Interest18 people have searched for VSTM on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Verastem to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $107.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Verastem is held by insiders.Percentage Held by Institutions88.37% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Verastem's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Verastem are expected to grow in the coming year, from ($3.54) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verastem is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verastem is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerastem has a P/B Ratio of 5.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Verastem's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Verastem Stock (NASDAQ:VSTM)Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.Read More VSTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VSTM Stock News HeadlinesSeptember 6 at 12:39 PM | seekingalpha.comVerastem's Path To FDA Approval: High-Risk, High-Reward Oncology OpportunitySeptember 4 at 1:31 AM | americanbankingnews.comVerastem, Inc. (NASDAQ:VSTM) Receives $14.83 Consensus PT from AnalystsSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 3, 2024 | financialpost.comVerastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024August 22, 2024 | markets.businessinsider.comOutperform Rating and $7 Target for Verastem Amidst LGSOC Treatment Potential and Stock Valuation OpportunityAugust 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verastem: Financial Stability and Promising Drug Pipeline Fuel OptimismAugust 9, 2024 | finance.yahoo.comVerastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business UpdatesAugust 9, 2024 | markets.businessinsider.comBuy Rating Justified by Verastem’s Promising LGSOC Drug Prospects and Strong Market PositionSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 9, 2024 | investorplace.comVSTM Stock Earnings: Verastem Beats EPS, Beats Revenue for Q2 2024August 4, 2024 | ca.finance.yahoo.comVSTM Aug 2024 2.000 callJuly 31, 2024 | investing.comVerastem Oncology receives FDA Orphan Drug DesignationJuly 30, 2024 | finance.yahoo.comVerastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic CancerJuly 24, 2024 | msn.comVerastem Oncology slumps 26%, prices $55M offeringJuly 24, 2024 | markets.businessinsider.comVerastem Oncology Announces Pricing Of $55.0 Mln Offering Of Common Stock, WarrantsJuly 24, 2024 | finance.yahoo.comVerastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded WarrantsJuly 23, 2024 | marketwatch.comVerastem Shares Drop 25% After Public Offering NewsJuly 23, 2024 | businesswire.comVerastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded WarrantsSee More Headlines Receive VSTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verastem and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:VSTM CUSIP92337C10 CIK1526119 Webwww.verastem.com Phone(781) 292-4200FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$14.83 High Stock Price Target$27.00 Low Stock Price Target$7.00 Potential Upside/Downside+518.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($4.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,370,000.00 Net MarginsN/A Pretax Margin-894.91% Return on Equity-194.05% Return on Assets-64.48% Debt Debt-to-Equity Ratio1.88 Current Ratio3.28 Quick Ratio3.28 Sales & Book Value Annual Sales$10 million Price / Sales6.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book5.11Miscellaneous Outstanding Shares25,326,000Free Float24,769,000Market Cap$60.78 million OptionableOptionable Beta0.16 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Daniel W. Paterson (Age 63)President, CEO & Director Comp: $697.98kMr. Daniel Calkins (Age 36)CFO and Principal Accounting & Financial Officer Comp: $1.42MMr. Richard H. Aldrich M.B.A. (Age 70)Founder and Consultant Comp: $38.39kDr. Robert A. Weinberg Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. Piyush B. Gupta Ph.D.Co-FounderDr. Michelle Dipp M.D. (Age 48)Ph.D., Co-Founder Mr. Robert Pintar M.B.A.Senior Vice President of Technical OperationsDr. Jonathan Pachter Ph.D. (Age 66)Chief Scientific Officer Comp: $238.18kMr. Nate SanburnSenior Vice President of Corporate Development & External EngagementDr. Hagop Youssoufian M.D. (Age 67)M.Sc., Ph.D., Head of Medical Strategy More ExecutivesKey CompetitorsMEI PharmaNASDAQ:MEIPEpizymeNASDAQ:EPZMXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCBought 400,000 shares on 8/20/2024Ownership: 0.994%Acadian Asset Management LLCBought 27,689 shares on 8/6/2024Ownership: 0.109%Rhumbline AdvisersBought 28,119 shares on 8/1/2024Ownership: 0.114%Bank of New York Mellon CorpBought 68,224 shares on 7/26/2024Ownership: 0.269%Daniel CalkinsSold 7 sharesTotal: $18.34 ($2.62/share)View All Insider TransactionsView All Institutional Transactions VSTM Stock Analysis - Frequently Asked Questions How have VSTM shares performed this year? Verastem's stock was trading at $8.14 on January 1st, 2024. Since then, VSTM shares have decreased by 70.5% and is now trading at $2.40. View the best growth stocks for 2024 here. How were Verastem's earnings last quarter? Verastem, Inc. (NASDAQ:VSTM) announced its quarterly earnings data on Thursday, August, 8th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.75. The biopharmaceutical company earned $10 million during the quarter. When did Verastem's stock split? Shares of Verastem reverse split on Thursday, June 1st 2023. The 1-12 reverse split was announced on Thursday, June 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. What is Robert Forrester's approval rating as Verastem's CEO? 11 employees have rated Verastem Chief Executive Officer Robert Forrester on Glassdoor.com. Robert Forrester has an approval rating of 100% among the company's employees. This puts Robert Forrester in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are Verastem's major shareholders? Verastem's top institutional shareholders include Nantahala Capital Management LLC (0.99%), Bank of New York Mellon Corp (0.27%), Rhumbline Advisers (0.11%) and Acadian Asset Management LLC (0.11%). Insiders that own company stock include Brian M Stuglik, Dan Paterson, Daniel Calkins and Robert E Gagnon. View institutional ownership trends. How do I buy shares of Verastem? Shares of VSTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Verastem own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (gild), Sorrento Therapeutics (SRNE) and SCYNEXIS (SCYX). This page (NASDAQ:VSTM) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verastem With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.